Close

Publications

Dib, F; MAYAUD, P; Renaudie, C; Launay, O; Chauvin, P;
2022
Human vaccines & immunotherapeutics, (2022).18 5 10.1080/21645515.2022.2083894.
MACKENZIE, GA; OSEI, I; Salaudeen, R; Hossain, I; Young, B; Secka, O; D'ALESSANDRO, U; Palmu, AA; Jokinen, J; Hinds, J; FLASCHE, S; Mulholland, K; Nguyen, C; GREENWOOD, B;
2022
Trials, (2022).23 1 10.1186/s13063-021-05964-5.
Echeverria-Londono, S; Hartner, A-M; Li, X; Roth, J; Portnoy, A; SBARRA, AN; ABBAS, K; Ferrari, M; FU, H; JIT, M; Ferguson, NM; Gaythorpe, KA M;
2022
Vaccine, (2022).40 47 10.1016/j.vaccine.2022.09.049.
DOCKRELL, HM;
2022
The Lancet. Infectious diseases, (2022).22 10 10.1016/s1473-3099(22)00287-0.
BELL, S; Clarke, RM; ISMAIL, SA; OJO-AROMOKUDU, O; Naqvi, H; Coghill, Y; Donovan, H; Letley, L; PATERSON, P; MOUNIER-JACK, S;
2022
PloS One, (2022).17 1 10.1371/journal.pone.0260949.
Lentzos, F; Rybicki, EP; Engelhard, M; PATERSON, P; Sandholtz, WA; Reeves, RG;
2022
Science (New York, N.Y.), (2022).375 6587 10.1126/science.abo1980.
Safety of the Ad26.ZEBOV/MVA-BN-Filo vaccine regimen in adults, children and pregnant women in DRC and immunogenicity of a delayed 2nd dose: the DRC-EB-001 trial.
WATSON-JONES, D;
2022
(2022).